Publications (20) View all
-
Article: Effects of Pitavastatin in Japanese Patients With Chronic Heart Failure.
[show abstract] [hide abstract]
ABSTRACT: Background: Recent clinical trials using rosuvastatin, a hydrophilic statin, did not show beneficial effects on cardiovascular events in patients with heart failure. We examined the cardioprotective effects of pitavastatin, a lipophilic statin, on Japanese patients with chronic heart failure (CHF). Methods and Results: A total of 574 Japanese patients with CHF were randomly assigned to the pitavastatin group (n=288) or the control group (n=286). There was no significant difference between the 2 groups for the primary outcome, which was a composite of cardiac death and hospitalization for worsening HF (adjusted hazard ratio (aHR): 0.922, 95% confidence interval (CI): 0.632-1.345, P=0.672). A strongly significant statistical interaction between the effect of pitavastatin and left ventricular ejection fraction (LVEF) was found (P=0.004). In patients with LVEF ≥30%, a significant reduction in the primary outcome (aHR: 0.525, 95% CI: 0.308-0.896, P=0.018) was observed in the pitavastatin group. Pitavastatin did not show any effects on the primary outcome (aHR: 1.582, 95% CI: 0.890-2.813, P=0.118) in the subgroup of patients with LVEF <30%. Conclusions: Pitavastatin did not reduce cardiac death or hospitalization for worsening HF in Japanese patients with CHF. (UMIN-ID: UMINC000000428).Circulation Journal 03/2013; · 3.77 Impact Factor -
Article: Sonographic confirmation of the association between calcified cerebral emboli and mitral annular calcification.
Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine 10/2010; 29(10):1507-10. · 1.25 Impact Factor -
Article: Pulmonary artery sarcoma.
Heart (British Cardiac Society) 01/2004; 89(12):1388. · 4.22 Impact Factor -
Article: Predictive value of high-molecular weight adiponectin in subjects with a higher risk of the development of metabolic syndrome: From a population based 5-year follow-up data.
International journal of cardiology 11/2012; · 7.08 Impact Factor -
Article: Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
[show abstract] [hide abstract]
ABSTRACT: Inflammation in the injured vessel wall plays an essential role in the mechanism of restenosis. Pentraxin3 (PTX3) is synthesized at the inflammatory site in response to primary inflammatory stimuli. To establish the clinical significance of plasma PTX3 levels in the pathophysiology of inflammation in the injured vessels, we serially measured the levels in 20 patients undergoing elective coronary stenting. Plasma PTX3 levels increased 15 min after coronary stenting, and reached a maximum at 24h in the coronary sinus (P<0.001 versus baseline) and peripheral blood (P<0.001 versus baseline). The transcardiac gradient of PTX3 at 15 min after PCI was higher in patients with than those without restenosis (0.40+/-0.64 versus -0.19+/-0.33 ng/ml, P=0.02). Furthermore, the increase in PTX3 at 24h was positively correlated with the increase in activated Mac-1 on the surface of neutrophils at 48 h (r=0.48, p<0.05) in the coronary sinus. Stepwise multiple regression analysis demonstrated that the relative increase in PTX3 at 24h was the most powerful predictor of late lumen loss (r=0.547, P=0.007). Coronary stenting enhanced circulating PTX3 levels in association with an inflammatory response. PTX3 may be a useful marker for evaluation of inflammatory reaction and neointimal thickening after vascular injury.Atherosclerosis 04/2008; 197(1):368-74. · 3.79 Impact Factor
